CIS43

Home
Ligands
CIS43

GtoPdb Ligand ID: 11254

Comment: CIS43 is a human monoclonal antibody directed against the P. falciparum circumsporozoite protein (PfCSP) [3]. The structure has not been formally disclosed and has not been curated by IMGT.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.

References
1. Flynn B, Kisalu N, Seder R, Idris A, Hoffman S. (2018) Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use. Patent number: WO2018148660. Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services. Priority date: 10/02/2017. Publication date: 16/08/2018.
2. Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, Gordon IJ, Plummer SH, Trofymenko O, Hu Z et al.. (2021) A Monoclonal Antibody for Malaria Prevention. N Engl J Med, 385 (9): 803-814. [PMID:34379916]
3. Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR et al.. (2018) A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med, 24 (4): 408-416. [PMID:29554083]
4. Kisalu NK, Pereira LD, Ernste K, Flores-Garcia Y, Idris AH, Asokan M, Dillon M, MacDonald S, Shi W, Chen X et al.. (2021) Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. JCI Insight, 6 (3). [PMID:33332286]

References

1. Flynn B, Kisalu N, Seder R, Idris A, Hoffman S. (2018)
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use.
Patent number: WO2018148660. Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services. Priority date: 10/02/2017. Publication date: 16/08/2018.

2. Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, Gordon IJ, Plummer SH, Trofymenko O, Hu Z et al.. (2021)
A Monoclonal Antibody for Malaria Prevention.
N Engl J Med, 385 (9): 803-814. [PMID:34379916]

3. Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR et al.. (2018)
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat Med, 24 (4): 408-416. [PMID:29554083]

4. Kisalu NK, Pereira LD, Ernste K, Flores-Garcia Y, Idris AH, Asokan M, Dillon M, MacDonald S, Shi W, Chen X et al.. (2021)
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention.
JCI Insight, 6 (3). [PMID:33332286]